

PRODUCT INFORMATION

Common Name SHR 1314;SHR-1314;SHR1314

Conjugate PE-conjugated

IL17;CTLA8;IL-17;ILA17;CTLA-8;IL-17A **Synonyms**

Applications Flow Cyt

Recommended

Flow Cyt 1:100 **Dilutions**

Formulation & Reconstitution

Liquid

□PBS with 0.05% Proclin300, 1% BSA

Host Species N/A lgG1 **IgG** type Reactivity Human **Target** IL17A 016552 **Uniprot ID**

PE-conjugated Anti-IL17A(vunakizumab **Description**

biosimilar) mAb

Delivery Under Development

Storage & Shipping Store at 2°C-8°C for 6 months

Research grade biosimilar. Not for use in **Background**

therapeutic or diagnostic procedures for humans

or animals.

Usage Research use only

> All DIMA recombinant antibodies are genuinely generated by DIMA Biotech. They are all under patent application. Any protein sequencing or reverse engineering attempt is prohibited. We are actively scrutinizing all patent application to

> > Email: info@dimabio.com Website: www.dimabio.com

DIMA Disclaimer

ensure no IP infringement.

